NCT02307279

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 436 (actual)
• Sponsor: Gelesis, Inc. · Industry
• Sex: All
• Age: 22 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.

Detailed description

To asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DEVICE	Gelesis100
DEVICE	placebo

Timeline

• Start date: 2014-11-01
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2014-12-04
• Last updated: 2022-08-30
• Results posted: 2022-08-30

Locations

36 sites across 6 countries: United States, Canada, Czechia, Denmark, Italy, Spain

Regulatory

• FDA-regulated device study